The genetics of breast cancer: Risk factors for disease

Application of Clinical Genetics

Volumn 4, Issue , 2011, Pages 11-19

  Collins, Andrew ^a   Politopoulos, Ioannis ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Bioinformatics; Breast cancer; Common and rare genetic variation; Exome sequencing; Missing heritability

Indexed keywords

BRCA1 INTERACTING PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CASPASE 8; CELL PROTEIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; LYMPHOCYTE SPECIFIC PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN P53; RAD51 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

BREAST CANCER; CANCER RISK; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HERITABILITY; HUMAN; ONCOGENE; PENETRANCE; PHENOTYPE; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 79953127113     PISSN: 1178704X     EISSN: None     Source Type: Journal    
DOI: 10.2147/TACG.S13139     Document Type: Review

References (57)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291): 1389-1399.
2. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250(4988):1684-1689.
3. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088-2090.
4. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008;40(1):17-22.
5. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91(11):943-949.
6. Bodmer W, Tomlinson I. Rare genetic variants and the risk of cancer. Curr Opin Genet Dev. 2010;20(3):262-267.
7. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171-182.
8. Yun MH, Hiom K. CtIP-BRCA1 modulates the choice of DNA doublestrand- break repair pathway throughout the cell cycle. Nature. 2009; 459(7245):460-463.
9. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol. 2010;11(2):138-148.
10. Jensen RB, Carreira A, Kowalczykowski SC. Purif ied human BRCA2 stimulates RAD51-mediated recombination. Nature. 2010; 467(7316):678-683.
11. Børresen AL, Andersen TI, Garber J, et al. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res. 1992; 52(11):3234-3236.
12. Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet. 1996; 13(1):114-116.
13. Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med. 1998; 128(11):896-899.
14. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene. 2006;25(43):5898-5905.
15. Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 2001;3(5):289-293.
16. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410-414.
17. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005; 97(11):813-822.
18. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39(2):165-167.
19. Robson M. CHEK2, breast cancer, and the understanding of clinical utility. Clin Genet. 2010;78(1):8-10.
20. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol. 2010; 8(1):e1000294.
21. Orozco G, Barrett JC, Zeggini E. Synthetic associations in the context of genome-wide association scan signals. Hum Mol Genet. 2010; 19(R2):R137-R144.
22. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009; 106(23):9362-9367.
23. 1000 Genomes Project Consortium, Durbin RM, Abecasis GR, Altshuler DL, et al. A map of human genome variation from populationscale sequencing. Nature. 2010;467(7319):1061-1073.
24. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39(7):870-874.
25. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447(7148):1087-1093.
26. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116-129.
27. Katoh Y, Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). Int J Mol Med. 2009;23(3):307-311.
28. Nilsson EM, Brokken LJ, Härkönen PL. Fibroblast growth factor 8 increases breast cancer cell growth by promoting cell cycle progression and by protecting against cell death. Exp Cell Res. 2010; 316(5):800-812.
29. Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007;39(3):352-358.
30. Latif A, Hadfield KD, Roberts SA, et al. Breast cancer susceptibility variants alter risks in familial disease. J Med Genet. 2010; 47(2):126-131.
31. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptorpositive breast cancer. Nat Genet. 2007;39(7):865-869.
32. Smid M, Wang Y, Klijn JG, et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol. 2006;24(15):2261-2267.
33. Udler MS, Ahmed S, Healey CS, et al. Fine scale mapping of the breast cancer 16q12 locus. Hum Mol Genet. 2010;19(12):2507-2515.
34. Rebbeck TR, DeMichele A, Tran TV, et al. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis. 2009;30(2):269-274.
35. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38(6):652-658.
36. Milne RL, Benítez J, Nevanlinna H, et al. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst. 2009;101(4):1012-1018.
37. Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet. 2009; 41(5):585-590.
38. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008;40(6):703-706.
39. Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 2010; 42(6):504-509.
40. Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009;41(5):579-584.
41. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 2008;4(4):e1000054.
42. Reeves GK, Travis RC, Green J, et al. Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci. JAMA. 2010;304(4):426-434.
43. Podo F, Buydens LM, Degani H, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010; 4(3):209-229.
44. Antoniou AC, Wang X, Fredericksen ZS, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010;42(10):885-892.
45. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008;358(26):2796-2803.
46. Gulcher J, Stefansson K. Genetic risk information for common diseases may indeed be already useful for prevention and early detection. Eur J Clin Invest. 2010;40(1):56-63.
47. Zhang W, Collins A, Morton NE. Does haplotype diversity predict power for association mapping of disease susceptibility? Hum Genet. 2004;115(2):157-164.
48. Allen HL, Estrada K, Lettre G, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature. 2010;467(7317):832-838.
49. Galvan A, Ioannidis JP, Dragani TA. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet. 2009;26(3):132-141.
50. Williams HJ, Owen MJ, O'Donovan MC. Schizophrenia genetics: new insights from new approaches. Br Med Bull. 2009;91:61-74.
51. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet. 2001;69(1):138-147.
52. Briollais L, Wang Y, Rajendram I, et al. Methodological issues in detecting gene-gene interactions in breast cancer susceptibility: a population-based study in Ontario. BMC Med. 2007;5:22.
53. Travis RC, Reeves GK, Green J, et al. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study Lancet. 2010;375(9732):2143-2151.
54. Spurdle AB, Chang JH, Byrnes GB, et al. A systematic approach to analysing gene-gene interactions: polymorphisms at the microsomal epoxide hydrolase EPHX and glutathione S-transferase GSTM1, GSTT1, and GSTP1 loci and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16(4):769-774.
55. Moore JH, Asselbergs FW, Williams SM. Bioinformatics challenges for genome-wide association studies. Bioinformatics. 2010; 26(4):445-455.
56. Gloyn AL, McCarthy MI. Variation across the allele frequency spectrum. Nat Genet. 2010;42(8):648-650.
57. Johansen CT, Wang J, Lanktree MB, et al. Excess of rare variants in genes identif ied by genome-wide association study of hypertriglyceridemia. Nat Genet. 2010;42(8):684-687.